

What is Claimed is:

- . 1. A prodrug complex comprising:
 - (a) a solected drug; and
- (b) a selected synthetic receptor which specifically 5 binds to the selected drug with a lower binding affinity than the selected drug for a targeted pathophysiologic, receptor.
- 2. The prodrug complex of claim 2 wherein a biologic or biocompatible structure is attached to the prodrug complex.
 - ∠
 A my/ti-prodrug complex comprising:
- 10 (a) at least two selected drugs; and
 - (b) at least two selected synthetic receptors which specifically bind to the selected drugs with a lower binding affinity than the selected drugs for targeted pathophysiologic receptors.
- 4. The multi-profiting complex of claim a wherein a biologic or biocompatible structure is attached to the multi-prodrug complex.
- A method of enhancing delivery of a selected drug to a targeted pathophysiologic receptor for said selected drug comprising:
 - (a) selecting a synthetic receptor which specifically binds a selected drug, said synthetic receptor having a lower binding affinity for the selected drug than a targeted pathophysiologic receptor for the selected drug;
- 25 (b) specifically binding the selected synthetic receptor to the selected drug to produce a prodrug complex; and
- (c) delivering the prodrug complex to the targeted pathophysiologic receptor so that the selected drug dissociates from the selected synthetic receptor and binds to the targeted pathophysiologic receptor.



The method of claim wherein step (b) further comprises attaching a biol dial or biocompatible structure to the selected drug or selected synthetic receptor.

- 23 -

- A method of enhancing delivery of selected drugs to **7**. 5 targeted pathophysiologic receptors for said selected drugs comprising:
- (a) selecting a synthetic receptor which specifically binds a selected drug, said synthetic receptor having a lower binding affintty for the selected drug than a targeted 10 pathophysiologic receptor for the selected drug;
 - (b) specifically binding at least two selected synthetic receptors to two selected drugs to produce a multi-prodrug complex; and
- (c) delivering the multi-prodrug complex to the targeted 15 pathophysiologid receptor so that the selected drugs dissociate from the selected synthetic receptors and bind to targeted pathophysiologic receptors.
- The method of claim wherein step (b) further comprises attaching a biological or biocompatible structure to 20 a selected synthetic receptor or selected drug.